FRDA has been the testing field for compounds which were further developed for the treatment of other disorders (Klopstock et al., 2011; Reata Pharmaceuticals, Inc., 2017) as well as the first neurodegenerative disease in which Erythropoietin (EPO) advanced to clinical trials (Boesch et al., 2007). Here, EPO is linked to neurodegenerative disease.